Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

LYPHOMED's PENTAMIDINE NDA ON "FAST TRACK" AT FDA with approval of the orphan drug anticipated for this summer, the firm's chairman John Kapoor indicated in his presentation to the Alex Brown Health Care seminar on May 21. Noting that pentamidine is used in the treatment of AIDS related Pneumocystis carinii pneumonia, Kapoor reported that LyphoMed received orphan status "about a month ago for this drug." Kapoor said that "the NDA is proceeding on the fast track through FDA and we hopefully will have an NDA [approval] in the next couple of months." Kapoor said that LyphoMed chose to supply the compound after receiving a call "six months ago" from the Centers of Disease Control (CDC). "We were able to deliver the product to them in six weeks and as a result they asked us to file for orphan drug status," Kapoor explained. In its most recent Morbidity and Mortality Weekly Report for May 18, CDC announced the availability of pentamidine under LyphoMed's IND. Up until now, CDC had distributed a foreign produced pentamidine manufactured by May & Baker. The LyphoMed exec explained that the firm will get increased exposure in the hospital market through sale of the orphan drug. "This product will probably be sold to every major institution in the country," Kapoor declared, "That's part of our strategy." A mfr. of micronutritionals and critical care injectable drugs for intravenous use, the Melrose Park, Illinois-based firm had sales of nearly $20 mil. in 1983 -- up from $6.3 mil. in 1981. Kapoor projected LyphoMed's 1984 sales to be in the "$28 mil.-$30 mil. range." The firm said in its recently released annual report for 1983 that it has received approval for 24 drug applications, "and 21 additional drug applications have been submitted and are awaiting approval." Currently under development, Kapoor said, are nitroglycerin IV, dopamine, glucagon, protamine, succinylcholine (B-W's Anectine), and bretylium tosylate (American Critical Care's Bretylol). Kapoor also noted that LyphoMed successfully raised nearly $13 mil. in 1983, via its initial public offering, for expansion of the firm's production facilities. "Right now, 30% of our units are being made by outside sources, which is very expensive," Kapoor said. "As soon as the plant is ready we're going to bring all that product in-house." He predicted that the plant would be completed this summer.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts